LIPOSOMES : A NOVEL DRUG DELIVERY SYSTEM

Priyanka R Kulkarni, Jaydeep D Yadav, K. A. Vaidya, D. M. V. P. Samaj 's
{"title":"LIPOSOMES : A NOVEL DRUG DELIVERY SYSTEM","authors":"Priyanka R Kulkarni, Jaydeep D Yadav, K. A. Vaidya, D. M. V. P. Samaj 's","doi":"10.56726/irjmets48594","DOIUrl":null,"url":null,"abstract":"Almost from the time of their discovery the demonstration of their entrapment potential, liposomal vesicles have drawn attention of researchers as potential carriers of various bioactive molecules that could be used for therapeutic applications. Liposomes have been widely investigated since 1970 as drug carriers for improving the delivery of therapeutic agents to specific sites in the body. Liposomes, which are biodegradable and essentially non‐toxic vehicles, can encapsulate both hydrophilic and hydrophobic materials, and are utilized as drug carriers in drug delivery systems. As a result, numerous improvements have been made, thus making this technology potentially useful for the treatment of certain diseases in the clinics. Many liposome‐based DNA delivery systems have been described, including molecular components for targeting given cell surface receptors or for escaping from the lysosomal compartment. The insight gained from clinical use of liposome drug delivery systems can now be integrated to design liposomes that can be targeted on tissues, cells or intracellular compartments with or without expression of target recognition molecules on liposome membranes. The success of liposomes as drug carriers has been reflected in a number of liposome‐based formulations, which are commercially available or are currently undergoing clinical trials.","PeriodicalId":505996,"journal":{"name":"International Research Journal of Modernization in Engineering Technology and Science","volume":"12 38","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Research Journal of Modernization in Engineering Technology and Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.56726/irjmets48594","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 14

Abstract

Almost from the time of their discovery the demonstration of their entrapment potential, liposomal vesicles have drawn attention of researchers as potential carriers of various bioactive molecules that could be used for therapeutic applications. Liposomes have been widely investigated since 1970 as drug carriers for improving the delivery of therapeutic agents to specific sites in the body. Liposomes, which are biodegradable and essentially non‐toxic vehicles, can encapsulate both hydrophilic and hydrophobic materials, and are utilized as drug carriers in drug delivery systems. As a result, numerous improvements have been made, thus making this technology potentially useful for the treatment of certain diseases in the clinics. Many liposome‐based DNA delivery systems have been described, including molecular components for targeting given cell surface receptors or for escaping from the lysosomal compartment. The insight gained from clinical use of liposome drug delivery systems can now be integrated to design liposomes that can be targeted on tissues, cells or intracellular compartments with or without expression of target recognition molecules on liposome membranes. The success of liposomes as drug carriers has been reflected in a number of liposome‐based formulations, which are commercially available or are currently undergoing clinical trials.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
脂质体 :一种新型给药系统
几乎从发现脂质体囊泡并证明其夹持潜力开始,脂质体囊泡就作为可用于治疗的各种生物活性分子的潜在载体引起了研究人员的关注。自 1970 年以来,人们一直在广泛研究脂质体作为药物载体如何将治疗药物更好地输送到体内特定部位。脂质体是一种可生物降解且基本无毒的载体,可以包裹亲水性和疏水性材料,在给药系统中被用作药物载体。因此,这项技术已经得到了许多改进,从而有可能在临床上用于治疗某些疾病。许多以脂质体为基础的 DNA 给药系统已被描述,其中包括用于靶向特定细胞表面受体或从溶酶体区逃逸的分子成分。从脂质体给药系统的临床应用中获得的洞察力现在可以整合到脂质体的设计中,无论脂质体膜上是否表达目标识别分子,脂质体都可以靶向组织、细胞或细胞内分区。脂质体作为药物载体所取得的成功体现在许多基于脂质体的制剂上,这些制剂已在市场上销售或正在进行临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
STUDY ON LINKAGES BETWEEN TRANSPORTATION AND QUALITY OF LIFE WITH AN EMPHASIS ON ACCESSIBILITY INDICATORS Performance Appraisal's Role in Employee Development: A Structured Equation Modeling Perspective at Etico Life Science Pvt Ltd A STUDY ON SMART HIGHWAY TRAFFIC MANAGEMENT USING INTELLIGENT TRANSPORTATION SYSTEM A Comprehensive Approach to Financial Portfolio Management with Cloud Infrastructure A Secure and Efficient Data store and Remote Data Integrity Checking in cloud computing Using TPA
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1